company background image
DUL logo

Alnylam Pharmaceuticals DB:DUL Stock Report

Last Price

€264.60

Market Cap

€34.3b

7D

1.1%

1Y

70.3%

Updated

06 Feb, 2025

Data

Company Financials +

Alnylam Pharmaceuticals, Inc.

DB:DUL Stock Report

Market Cap: €34.3b

DUL Stock Overview

A biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More details

DUL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Alnylam Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$264.60
52 Week HighUS$276.90
52 Week LowUS$132.70
Beta0.35
1 Month Change19.03%
3 Month Change5.50%
1 Year Change70.27%
3 Year Change100.76%
5 Year Change117.56%
Change since IPO5,300.00%

Recent News & Updates

Recent updates

Shareholder Returns

DULDE BiotechsDE Market
7D1.1%2.3%0.5%
1Y70.3%-2.6%15.3%

Return vs Industry: DUL exceeded the German Biotechs industry which returned -4.6% over the past year.

Return vs Market: DUL exceeded the German Market which returned 13.7% over the past year.

Price Volatility

Is DUL's price volatile compared to industry and market?
DUL volatility
DUL Average Weekly Movement5.7%
Biotechs Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: DUL has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: DUL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,100Yvonne Greenstreetwww.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
DUL fundamental statistics
Market cap€34.31b
Earnings (TTM)-€319.87m
Revenue (TTM)€2.02b

17.1x

P/S Ratio

-108.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DUL income statement (TTM)
RevenueUS$2.09b
Cost of RevenueUS$306.41m
Gross ProfitUS$1.79b
Other ExpensesUS$2.12b
Earnings-US$332.26m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)-2.58
Gross Margin85.37%
Net Profit Margin-15.86%
Debt/Equity Ratio7,566.4%

How did DUL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 21:25
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 65 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg